Corteria Pharmaceuticals is focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure, sarcopenia, and obesity subpopulations
Corteria Pharmaceuticals is focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure, sarcopenia, and obesity subpopulations. The company is developing first-in-class drugs for indications of high unmet medical need, utilizing innovative patient stratification and target selection based on human evidence.